Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Reduced risk of disease during postsecondary dengue virus infections.

Olkowski S, Forshey BM, Morrison AC, Rocha C, Vilcarromero S, Halsey ES, Kochel TJ, Scott TW, Stoddard ST.

J Infect Dis. 2013 Sep;208(6):1026-33. doi: 10.1093/infdis/jit273. Epub 2013 Jun 17.

2.

Spatial dimensions of dengue virus transmission across interepidemic and epidemic periods in Iquitos, Peru (1999-2003).

Liebman KA, Stoddard ST, Morrison AC, Rocha C, Minnick S, Sihuincha M, Russell KL, Olson JG, Blair PJ, Watts DM, Kochel T, Scott TW.

PLoS Negl Trop Dis. 2012;6(2):e1472. doi: 10.1371/journal.pntd.0001472. Epub 2012 Feb 21.

4.

Serotype-specific and cross-reactive neutralizing antibody responses in cynomolgus monkeys after infection with multiple dengue virus serotypes.

Ito M, Katakai Y, Ono F, Akari H, Mukai RZ, Takasaki T, Kotaki A, Kurane I.

Arch Virol. 2011 Jun;156(6):1073-7. doi: 10.1007/s00705-011-0959-2. Epub 2011 Mar 16.

PMID:
21409446
5.

[Prevalence of neutralizing antibodies to dengue virus serotypes in university students from Tabasco, Mexico].

Sánchez-Burgos GG, López-Alvarado MA, Castañeda-Desales D, Ruiz-Gómez J, Ramos-Castañeda J.

Salud Publica Mex. 2008 Sep-Oct;50(5):362-6. Spanish.

6.

Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.

Sasaki T, Setthapramote C, Kurosu T, Nishimura M, Asai A, Omokoko MD, Pipattanaboon C, Pitaksajjakul P, Limkittikul K, Subchareon A, Chaichana P, Okabayashi T, Hirai I, Leaungwutiwong P, Misaki R, Fujiyama K, Ono K, Okuno Y, Ramasoota P, Ikuta K.

Antiviral Res. 2013 Jun;98(3):423-31. doi: 10.1016/j.antiviral.2013.03.018. Epub 2013 Mar 29.

PMID:
23545366
7.

Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection.

Setthapramote C, Sasaki T, Puiprom O, Limkittikul K, Pitaksajjakul P, Pipattanaboon C, Sasayama M, Leuangwutiwong P, Phumratanaprapin W, Chamnachanan S, Kusolsuk T, Jittmittraphap A, Asai A, Arias JF, Hirai I, Kuhara M, Okuno Y, Kurosu T, Ramasoota P, Ikuta K.

Biochem Biophys Res Commun. 2012 Jul 13;423(4):867-72. doi: 10.1016/j.bbrc.2012.06.057. Epub 2012 Jun 17. Erratum in: Biochem Biophys Res Commun. 2013 Mar 1;432(1):200-1.

PMID:
22713454
8.

Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies.

Buddhari D, Aldstadt J, Endy TP, Srikiatkhachorn A, Thaisomboonsuk B, Klungthong C, Nisalak A, Khuntirat B, Jarman RG, Fernandez S, Thomas SJ, Scott TW, Rothman AL, Yoon IK.

PLoS Negl Trop Dis. 2014 Oct 16;8(10):e3230. doi: 10.1371/journal.pntd.0003230. eCollection 2014 Oct.

9.

Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort.

Katzelnick LC, Montoya M, Gresh L, Balmaseda A, Harris E.

Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):728-33. doi: 10.1073/pnas.1522136113. Epub 2016 Jan 4.

10.

Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year.

Montoya M, Gresh L, Mercado JC, Williams KL, Vargas MJ, Gutierrez G, Kuan G, Gordon A, Balmaseda A, Harris E.

PLoS Negl Trop Dis. 2013 Aug 8;7(8):e2357. doi: 10.1371/journal.pntd.0002357. eCollection 2013.

11.

Retrospective serological study on sequential dengue virus serotypes 1 to 4 epidemics in Tainan City, Taiwan, 1994 to 2000.

Chang SF, Huang JH, Chen LK, Su CL, Liao TL, Chien LJ, Lin TH, Su CJ, Shu PY.

J Microbiol Immunol Infect. 2008 Oct;41(5):377-85.

PMID:
19122918
12.

Incomplete Protection against Dengue Virus Type 2 Re-infection in Peru.

Forshey BM, Reiner RC, Olkowski S, Morrison AC, Espinoza A, Long KC, Vilcarromero S, Casanova W, Wearing HJ, Halsey ES, Kochel TJ, Scott TW, Stoddard ST.

PLoS Negl Trop Dis. 2016 Feb 5;10(2):e0004398. doi: 10.1371/journal.pntd.0004398. eCollection 2016 Feb.

13.

Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection.

Moi ML, Takasaki T, Saijo M, Kurane I.

Trans R Soc Trop Med Hyg. 2013 Jan;107(1):51-8. doi: 10.1093/trstmh/trs007.

PMID:
23296697
14.

Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort.

Corbett KS, Katzelnick L, Tissera H, Amerasinghe A, de Silva AD, de Silva AM.

J Infect Dis. 2015 Feb 15;211(4):590-9. doi: 10.1093/infdis/jiu481. Epub 2014 Oct 21.

15.

[Analysis of serum neutralizing antibody response in patients with primary dengue virus type 1 infection].

Hu D, Li J, Wang D, DI B, Qiu L, Wang Y, Ding X, Che X.

Nan Fang Yi Ke Da Xue Xue Bao. 2012 Dec;32(12):1773-6, 1791. Chinese.

16.

Neutralizing antibodies after infection with dengue 1 virus.

Guzman MG, Alvarez M, Rodriguez-Roche R, Bernardo L, Montes T, Vazquez S, Morier L, Alvarez A, Gould EA, Kouri G, Halstead SB.

Emerg Infect Dis. 2007 Feb;13(2):282-6.

17.

Demonstration of marmosets (Callithrix jacchus) as a non-human primate model for secondary dengue virus infection: high levels of viraemia and serotype cross-reactive antibody responses consistent with secondary infection of humans.

Moi ML, Takasaki T, Omatsu T, Nakamura S, Katakai Y, Ami Y, Suzaki Y, Saijo M, Akari H, Kurane I.

J Gen Virol. 2014 Mar;95(Pt 3):591-600. doi: 10.1099/vir.0.060384-0. Epub 2013 Dec 9.

PMID:
24323638
18.

Inferring the serotype associated with dengue virus infections on the basis of pre- and postinfection neutralizing antibody titers.

van Panhuis WG, Gibbons RV, Endy TP, Rothman AL, Srikiatkhachorn A, Nisalak A, Burke DS, Cummings DA.

J Infect Dis. 2010 Oct 1;202(7):1002-10. doi: 10.1086/656141.

19.

[Concurrent infections by two dengue virus serotypes during an outbreak in northwestern Peru, 2008].

Mamani E, Figueroa D, García MP, Garaycochea Mdel C, Pozo EJ.

Rev Peru Med Exp Salud Publica. 2010 Mar;27(1):16-21. Spanish.

20.

Recombinant envelope protein-based enzyme immunoassay for IgG antibodies is comparable to neutralization tests for epidemiological studies of dengue infection.

Rocha ES, Oliveira JG, Santos JR, Rodrigues GO, Figueiredo LB, Pessanha JE, Proietti FA, Fonseca FG, Bonjardim CA, Ferreira PC, Kroon EG.

J Virol Methods. 2013 Jan;187(1):114-20. doi: 10.1016/j.jviromet.2012.09.012. Epub 2012 Sep 24.

Supplemental Content

Support Center